Douglas Pharmaceuticals Europe Limited
Douglas Pharmaceuticals Europe Limited, a prominent player in the pharmaceutical industry, is headquartered in the United Kingdom and operates extensively across Europe. Founded in 1990, the company has established itself as a leader in the development and manufacturing of high-quality generic and branded pharmaceuticals. Specialising in prescription medications, Douglas Pharmaceuticals is recognised for its commitment to innovation and quality, offering a diverse portfolio that includes both over-the-counter and prescription products. The company’s unique approach to product development and stringent quality control measures have positioned it favourably within the competitive landscape. With a strong market presence and notable achievements in regulatory compliance, Douglas Pharmaceuticals Europe Limited continues to enhance its reputation as a trusted provider of healthcare solutions, dedicated to improving patient outcomes across the continent.
DitchCarbon Score
How does Douglas Pharmaceuticals Europe Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Retail Trade Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Douglas Pharmaceuticals Europe Limited's score of 26 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Douglas Pharmaceuticals Europe Limited's reported carbon emissions
Douglas Pharmaceuticals Europe Limited has set an ambitious commitment to achieve net zero carbon emissions by 2050, encompassing all scopes of emissions. While specific emissions data for the most recent year is not available, the company is actively working towards this long-term goal, which reflects a growing trend in the pharmaceutical industry to address climate change. The commitment to net zero indicates a comprehensive approach to reducing carbon emissions across all operations, aligning with global climate initiatives. Douglas Pharmaceuticals is likely to implement various strategies and initiatives to meet this target, although detailed reduction percentages and interim goals have not been specified. As the company progresses towards its 2050 target, it will be essential to monitor their initiatives and any future disclosures regarding emissions data and reduction achievements. This commitment positions Douglas Pharmaceuticals as a proactive player in the industry, contributing to broader efforts to mitigate climate change impacts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Douglas Pharmaceuticals Europe Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
